A possible underlying mechanism is based on TGF-β release by tumor cells, because of its high serum level characterizing GC patients that is negatively correlated with the frequency of NK cells expressing NKp46, NKp30 but also NKG2D and DNAM1 [114]. The gene discussed is NCR3; the disease is neoplasm.